Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, up 7.5% year-on-year, with earnings per share at HKD 0.1141 and an interim dividend of HKD 0.022 per share proposed [1] Revenue Growth - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with a 31.4% increase in sales of the injection product Qufrener (芮旎尔®) and a 12.9% increase in Budesonide (布累迪宁®) [1] - The introduced product Fipril (菲普利®) saw a significant growth of 33.3%, regaining its position as the largest contributor after a transitional phase last year [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in revenue growth, with the injection product Sodium Dexamethasone (立畅青®) and Enoxaparin Sodium (立腾菁®) achieving growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]
李氏大药厂(00950)发布中期业绩，股东应占溢利6718.5万港元 同比增加7.5%